Urogen Pharma

URGN Healthcare Biotechnology

Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 199.2%, EPS grew 73.3%, free cash flow grew 17.3% and total debt rose 56.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

34.56 2.05 −5.60%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
−30.0×
Dividend yield
—
F-score
2/9
Altman Z
−5.16
Beneish M
−1.42
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 3 2 2

+8 more TTM periods

ROE
86.49% 156.08% 268.63% 366.31%
ROA
(42.33%) (53.15%) (63.14%) (67.62%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(56.08%) (71.07%) (109.45%) (129.64%)
Average Days of Receivables
171.65 143.96 109.98 74.51
Free Cash Flow per Share
(3.16) (3.31) (3.38) (2.87)
Free Cash Flow
(159.13) (166.03) (162.73) (138.12)
Capital Expenditures
(0.22) (0.30) (0.29) (0.39)
Other line items
Cash ROIC
(94.40%) (80.26%) (114.59%) (102.25%)
Accounts Receivable Turnover
3.48 3.74 4.11 4.54
Accounts Payable Turnover
0.49 0.43 0.45 0.51
Inventory Turnover
1.09 1.00 0.97 1.46
Average Days of Payables
843.84 904.97 812.78 821.49
Days of Inventory on Hand
519.45 535.65 482.80 261.80
Tax Rate
0.00 (0.04) 0.00 0.02
Research and Development Expense of Revenue
32.46% 44.72% 61.12% 70.13%
Selling, General and Administrative Expense of Revenue
93.71% 122.15% 141.27% 156.04%
Share Based Compensation of Revenue
8.54% 9.62% 10.89% 12.57%
Interest Coverage
(4.11) (7.00) (8.14) (8.63)
Operating CF/Net income
1.63 1.24 1.06 0.84
Depreciation/Fixed assets
(2.62) (1.24) (2.46) (4.08)
Capex/Depreciation
0.14 0.39 0.18 0.14
Revenue per Share
3.75 2.80 2.28 2.01
Operating CF per Share
(3.15) (3.30) (3.38) (2.87)
Capex per Share
0.00 (0.01) (0.01) (0.01)
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates